Table 1.
Summary table of the main studies included in the literature review that evaluated the prognostic role of preoperative inflammation-based scores.
| Marker | Reference | Study Design | Sample Size | Treatment | Cut-off value | p-Value | Statistical Method | Endpoint |
|---|---|---|---|---|---|---|---|---|
| NLR | Li (2020) | Metanalysis | 4023 | TACE | 5 2.5–5 2.5 |
<0.00001 <0.00001 <0.00001 |
Random Effect Fixed Effect Fixed Effect |
OS |
| NLR | Xiao (2014) | Metanalysis | 302 | TACE | NA | <0.0001 | Fixed Effect | OS |
| NLR | Cho (2022) | Retrospective | 605 | cTACE | 1.7 1.7 |
0.007 <0.001 |
Cox (ROC) Cox (ROC) |
TTP OS |
| NLR | Chu (2021) | Retrospective | 495 | cTACE | 3 3 |
0.007 <0.001 |
Cox (ROC) Logistic Regr. |
OS 6m-PD * |
| NLR | Wang (2020) | Retrospective | 380 | cTACE | 2.4 | 0.027 | Cox (Median) | OS |
| NLR | Liu (2020) | Retrospective | 180 | cTACE | 3.94 | <0.001 | Cox (ROC) | OS |
| NLR | Schobert (2020) | Retrospective | 46 | DEB-TACE | NA 3.22 |
0.014 0.002 |
Linear Regr. Cox (Mean) |
ETV ** PFS |
| NLR | He (2019) | Retrospective | 216 | cTACE | 1.77 | <0.0001 | Log-rank | OS |
| NLR | Rebonato (2017) | Retrospective | 72 | DEB-TACE | 2.03 | 0.0028 | Cox (median) | OS |
| NLR | Fan (2015) | Retrospective | 132 | cTACE | 3.1 | 0.130 | Cox (mean) | OS |
| LMR | Wang (2022) | Prospective | 606 | cTACE + ablation |
2.27 † 2.27 † 2.27 † |
0.022 0.029 0.011 |
Cox (Youden) Cox (Youden) Logistic Regr. |
RFS OS 2y-Recurrence |
| LMR | Liu (2021) | Retrospective | 128 | TACE | 4.4 | 0.236 | Cox (ROC) | PFS |
| LMR | Liu (2020) | Retrospective | 180 | cTACE | 2.2 | <0.001 | Cox (ROC) | OS |
| LMR | Shen (2019) | Retrospective | 204 | cTACE + RFA | 2.13 | <0.0001 | Cox (ROC) | OS |
| PLR | Li (2020) | Metanalysis | 856 | TACE | NA | 0.007 | Random effect | OS |
| PLR | Liu (2021) | Retrospective | 128 | TACE | 92 | 0.000195 | Cox (ROC) | PFS |
| PLR | Chen (2020) | Retrospective | 134 | cTACE + apatinib |
150 | 0.014 | Cox | OS |
| PLR | Schobert (2020) | Retrospective | 46 | DEB TACE | NA 113.1 |
0.004 <0.001 |
Linear Regr. Cox (mean) |
ETV * PFS |
| PLR | He (2019) | Retrospective | 216 | cTACE | 94.62 | 0.0022 | Log-rank | OS |
| PLR | Shen (2019) | Retrospective | 204 | cTACE + RFA | 95.65 | <0.0001 | Cox (ROC) | OS |
| PLR | Xue (2015) | Retrospective | 291 | cTACE | 150 | 0.002 | Cox (chi-square) | OS |
| PLR | Fan (2015) | Retrospective | 132 | cTACE | 137 | <0.001 | Cox (mean) | OS |
| LCR | Lu (2021) | Retrospective | 1625 | cTACE | 6000 | <0.001 | Cox (ROC) | OS |
* 6m-PD—progressive disease at 6 months; ** ETV—enhancing tumor volume; †—calculated with the formula 1/MLR.